(Q33382342)

English

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Evanthia Galanis

11

object named as

Evanthia Galanis

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marta Santisteban

1

object named as

Marta Santisteban

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bernd Walter Scheithauer

5

object named as

Bernd W Scheithauer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Jan C Buckner

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joel M Reid

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wenting Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Matthew M Ames

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sara J Felten

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daniel A Nikcevich

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Wiesenfeld

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kurt A Jaeckle

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

North Central Cancer Treatment Group

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

10 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

165-175

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s11060-008-9749-4

0 references

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

A mechanistic approach to antiepileptic drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

21 June 2018

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Metabolic enzymes and antiepileptic drug interactions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2721337

31 October 2018

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical study of CPT-11. Research group of CPT-11

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-008-9749-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33382342&oldid=2143342418"